Baroda BNP Paribas Mutual Fund
When comparing, both lines start at 100. Tradinity's reference for the category: a total-return index (dividends reinvested). The fund's declared benchmark (BSE Healthcare Total Return Index) is not available to us as a series.
This is an IDCW (dividend) option: it pays cash out of its NAV, so returns computed from the NAV alone would understate what an investor earned. See the Growth option of the same plan for performance.
Computed from this fund's actual NAVs. A SIP buys at the first NAV of each month and is valued at the latest NAV. Past returns do not guarantee future ones.
Weights are % of the scheme's assets from the latest month-end disclosure available to Tradinity. Shown from the Direct plan of this fund, which holds the same portfolio. The feed carries weights only: no quantities or rupee values.
Valuation ratios are weighted over the holdings we can match to a company (harmonic mean for P/E) and are withheld when they cover under half the portfolio.
| Holding | Sector | Weight | 3M change | P/E |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Limited | Healthcare | 9.01% | — | 143.5 |
| Divi's Laboratories Limited | Healthcare | 8.01% | — | 83.0 |
| Torrent Pharmaceuticals Limited | Healthcare | 7.99% | — | 77.7 |
| IPCA Laboratories Limited | Healthcare | 6.23% | — | 39.8 |
| Lupin Limited | Healthcare | 5.99% | — | 13.2 |
| Laurus Labs Limited | Healthcare | 5.66% | — | 122.0 |
| Apollo Hospitals Enterprise Limited | Healthcare | 5.44% | — | 73.1 |
| Fortis Healthcare Limited | Healthcare | 4.50% | — | 255.5 |
| AstraZeneca Pharma India Limited | Healthcare | 3.56% | — | 87.1 |
| Glenmark Pharmaceuticals Limited | Healthcare | 3.42% | — | 316.1 |
| Dr. Lal Path Labs Limited | Healthcare | 3.24% | — | 38.4 |
| Mankind Pharma Limited | Healthcare | 3.10% | — | 46.9 |
| Aurobindo Pharma Limited | Healthcare | 3.05% | — | 37.5 |
| Max Financial Services Limited | Financial Services | 2.43% | — | — |
| Emcure Pharmaceuticals Limited | Healthcare | 2.38% | — | 45.3 |
| Abbott India Limited | Healthcare | 2.29% | — | 34.5 |
| Acutaas Chemicals Limited | Healthcare | 2.24% | — | 64.3 |
| Aster DM Quality Care Limited | Healthcare | 2.23% | — | 205.8 |
| Zydus Lifesciences Limited | Healthcare | 2.15% | — | 32.6 |
| Concord Biotech Limited | Healthcare | 2.14% | — | 50.3 |
| Ajanta Pharma Limited | Healthcare | 1.49% | — | 43.2 |
| Metropolis Healthcare Limited | Healthcare | 1.49% | — | 28.1 |
| Nephrocare Health Services Ltd | Healthcare | 1.35% | — | — |
| Manipal Health Enterprises Ltd | Healthcare | 1.27% | — | — |
| Symbiotec Pharmalab Limited | Healthcare | 1.18% | — | — |
| Dr. Reddy's Laboratories Limited | Healthcare | 1.14% | — | 150.9 |
| Gland Pharma Limited | Healthcare | 1.14% | — | 34.4 |
| Cipla Limited | Healthcare | 1.11% | — | 35.1 |
| Clearing Corporation of India Ltd | — | 1.02% | — | — |
| MedPlus Health Services Limited | Consumer Services | 0.93% | — | 116.5 |
| Inventurus Knowledge Solutions Limited | Information Technology | 0.85% | — | 48.0 |
| GlaxoSmithKline Pharmaceuticals Limited | Healthcare | 0.72% | — | 43.8 |
| Procter & Gamble Health Limited | Healthcare | 0.57% | — | 24.7 |
| Life Insurance Corporation Of India | Financial Services | 0.48% | — | — |
| Net Receivables / (Payables) | — | 0.20% | — | — |
This is a paid feature
Comparing more months of this fund's own portfolio history is available on paid plans.
Sign inExpense ratio by month: Oct 25 2.28% · Nov 25 2.28% · Dec 25 2.32% · Jan 26 2.33% · Feb 26 2.33% · Mar 26 2.33% · Apr 26 2.46% · May 26 2.45% · Jun 26 2.74% · Jul 26 2.78% · Aug 26 2.79% · Sep 26 2.74%
Redemption/ switch out of units upto 10% of the units allotted before 1 year from date of allotment- Exit load -NIL; For redemption/switch out of units above 10% of units allotted within 1 year from the date of allotment- 1.00% of applicable NAV; For redemption/switch out of units after 1 year from the date of allotment-Nil
The primary objective of the Scheme is to provide long-term capital appreciation by investing predominantly in equity and equity related instruments of Pharma and Healthcare companies. The Scheme does not guarantee/indicate any returns. However, there can be no assurance that the investment objective of the Scheme will be realized.
Fund house: website · factsheets · monthly portfolio · annual report
Not available: Morningstar rating (proprietary). "NAV history from" is the first NAV we hold.
Returns are computed by Tradinity from each scheme's own published NAV, so they are net of the fund's expenses. Periods over one year are annualised (CAGR). Past performance does not indicate future returns. Only Growth-option schemes are ranked: an IDCW scheme pays cash out of its NAV, so its NAV understates what an investor earned.
